Oliver Sum-Ping, MD, a Clinical Associate Professor of Psychiatry and Sleep Medicine at Stanford Medicine who wasnt affiliated with the research told Healthline, The results suggest substantial potential for the role of these medications for at least mitigating OSA. The SURMOUNT-OSA trial was a multi-center, randomized, double-blind, placebo-controlled trial conducted with 469 patients, all of whom had OSA
All four of these enzymes are referred to as ABC enzymes because they require/utilize A TP, B iotin, and C O 2
While these medications offer significant benefits, it's essential to be aware of their safety profile and potential side effects
Obesity pharmacotherapy is a rapidly moving field and further research on long-term clinical efficacy, safety and cost-effectiveness will inform better their place in the treatment algorithms for obesity and obesity-related complications over the next years